{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T18:44:54Z","timestamp":1787942694527,"version":"build-2784847793"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2017,9,2]],"date-time":"2017-09-02T00:00:00Z","timestamp":1504310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"},{"start":{"date-parts":[[2017,9,2]],"date-time":"2017-09-02T00:00:00Z","timestamp":1504310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["jsm.jsexmed.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Peyronie\u2019s disease (PD), defined as the abnormal formation of fibrous plaque(s) in the tunica albuginea of the penis, is a chronic condition that afflicts 3% to 13% of the US male population; there is no current research on the efficacy and safety of collagenase Clostridium histolyticum (CCH) in the treatment of acute phase PD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To examine the efficacy and safety of CCH in the treatment of acute-phase PD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively reviewed the records for all patients treated with CCH for PD from April 2014 through April 2017. Patients who reported penile pain and duration of PD no longer than 12 months at presentation qualified as being in the acute phase of PD. The primary outcomes of interest were final changes in curvature after CCH treatment regardless of the number of CCH cycles received and frequency of treatment-related adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes<\/jats:title>\n                    <jats:p>Parameters of efficacy and safety were compared between acute- and stable-phase PD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 162 patients were included in the study, of which 36 (22%) qualified as having acute-phase PD (group 1) and the remaining 126 (78%) qualified as having stable-phase PD (group 2). Median duration of\u00a0PD was 8.5 months (range\u00a0= 1\u201312) for group 1 and 18 months (range\u00a0= 1\u2013492) for group 2. There was no\u00a0significant difference in final change in curvature between the acute and stable phases of PD (16.7\u00b0 vs 15.6\u00b0; P\u00a0= .654). There was no statistically significant difference in frequency of treatment-related adverse events between the acute phase (4 patients, 11%) and the stable phase (12 patients, 10%; P\u00a0= .778).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Implications<\/jats:title>\n                    <jats:p>CCH therapy is as safe and efficacious in acute-phase PD as it is in stable-phase PD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Strengths and Limitations<\/jats:title>\n                    <jats:p>This is the first report that assesses the safety and efficacy of CCH therapy focusing on acute-phase PD. This study was composed of a large cohort of patients receiving CCH therapy in acute- and stable-phase PD. Limitations include bias associated with retrospective studies, a small sample, and a single-center setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Although CCH is not clearly indicated for treatment during the acute phase of PD, these results suggest that CCH use during this phase can be effective and safe. There was no statistically significant difference in final change in curvature or treatment-related adverse events after CCH therapy delivered between the acute and stable phases of PD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1016\/j.jsxm.2017.08.008","type":"journal-article","created":{"date-parts":[[2017,9,2]],"date-time":"2017-09-02T13:30:15Z","timestamp":1504359015000},"page":"1220-1225","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"title":["Safety and Efficacy of Collagenase\n                    <i>Clostridium histolyticum<\/i>\n                    in the Treatment of Acute-Phase Peyronie\u2019s Disease"],"prefix":"10.1093","volume":"14","author":[{"given":"Hoang Minh Tue","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Anaissie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth J.","family":"DeLay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faysal A.","family":"Yafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suresh C.","family":"Sikka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne J.G.","family":"Hellstrom","sequence":"additional","affiliation":[{"name":"Department of Urology \u00a0 , New Orleans, LA , USA"},{"name":"Tulane University School of Medicine \u00a0 , New Orleans, LA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,9,2]]},"reference":[{"key":"2023011110492832000_bib1","first-page":"1007","article-title":"The incidence of Peyronie\u2019s\u2019s disease in Rochester, Minnesota, 1950 through 1984","volume":"146","author":"Lindsay","year":"1991","journal-title":"J\u00a0Urol"},{"key":"2023011110492832000_bib2","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/sj.ijir.3900863","article-title":"Epidemiology of Peyronie\u2019s\u2019s disease","volume":"14","author":"Sommer","year":"2002","journal-title":"Int J Impot Res"},{"key":"2023011110492832000_bib3","first-page":"2350","article-title":"Subjective and objective analysis of the prevalence of Peyronie\u2019s\u2019s disease in a population of men presenting for prostate cancer screening","volume":"171","author":"Mulhall","year":"2004","journal-title":"J\u00a0Urol"},{"key":"2023011110492832000_bib4","doi-asserted-by":"crossref","first-page":"282503","DOI":"10.1155\/2011\/282503","article-title":"A\u00a0population-based study of Peyronie\u2019s\u2019s disease: prevalence and treatment patterns in the United States","volume":"2011","author":"Dibenedetti","year":"2011","journal-title":"Adv Urol"},{"key":"2023011110492832000_bib5","first-page":"1376","article-title":"The natural history of Peyronie\u2019s\u2019s disease","volume":"144","author":"Gelbard","year":"1990","journal-title":"J\u00a0Urol"},{"key":"2023011110492832000_bib6","first-page":"1985","article-title":"The chronology of depression and distress in men with Peyronie\u2019s\u2019s disease","volume":"5","author":"Nelson","year":"2008","journal-title":"J\u00a0Sex Med"},{"key":"2023011110492832000_bib7","first-page":"2179","article-title":"Risk factors for emotional and relationship problems in Peyronie\u2019s\u2019s disease","volume":"5","author":"Smith","year":"2008","journal-title":"J\u00a0Sex Med"},{"key":"2023011110492832000_bib8","first-page":"653","article-title":"Psychological impact of Peyronie\u2019s\u2019s disease: a review","volume":"10","author":"Nelson","year":"2013","journal-title":"J\u00a0Sex Med"},{"key":"2023011110492832000_bib9","first-page":"745","article-title":"Peyronie\u2019s\u2019s disease: AUA guideline","volume":"194","author":"Nehra","year":"2015","journal-title":"J\u00a0Urol"},{"key":"2023011110492832000_bib10","first-page":"1209","article-title":"The use of collagenase in the treatment of Peyronie\u2019s\u2019s disease M.K. Gelbard, A. Lindner, and J.J. Kaufman","volume":"4","author":"Glina","year":"2007","journal-title":"J\u00a0Sex Med"},{"key":"2023011110492832000_bib11","first-page":"199","article-title":"Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of Peyronie\u2019s disease in 2 large double-blind, randomized, placebo controlled phase 3 studies","volume":"190","author":"Gelbard","year":"2013","journal-title":"J\u00a0Urol"},{"key":"2023011110492832000_bib12","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.urology.2016.04.049","article-title":"Peyronie\u2019s\u2019s disease and injectable collagenase Clostridium histolyticum: safety, efficacy, and improvements in subjective symptoms","volume":"94","author":"Yang","year":"2016","journal-title":"Urology"},{"key":"2023011110492832000_bib13","first-page":"1051","article-title":"Restoration of penile function and patient satisfaction with intralesional collagenase Clostridium histolyticum injection for Peyronie\u2019s\u2019s disease","volume":"195","author":"Ziegelmann","year":"2016","journal-title":"J\u00a0Urol"},{"key":"2023011110492832000_bib14","doi-asserted-by":"crossref","first-page":"114","DOI":"10.21037\/tau.2016.12.09","article-title":"Expanding the role of injectable collagenase Clostridium histolyticum for the treatment of active phase Peyronie\u2019s\u2019s disease","volume":"6","author":"Aliperti","year":"2017","journal-title":"Transl Androl Urol"},{"key":"2023011110492832000_bib15","first-page":"2115","article-title":"An analysis of the natural history of Peyronie\u2019s\u2019s disease","volume":"175","author":"Mulhall","year":"2006","journal-title":"J\u00a0Urol"}],"container-title":["The Journal of Sexual Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609517313796?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609517313796?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/14\/10\/1220\/48525145\/jsm_14_10_1220.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/14\/10\/1220\/48525145\/jsm_14_10_1220.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T09:36:33Z","timestamp":1673429793000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jsm\/article\/14\/10\/1220\/6973322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,2]]},"references-count":15,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2017,9,2]]},"published-print":{"date-parts":[[2017,10,1]]}},"URL":"https:\/\/doi.org\/10.1016\/j.jsxm.2017.08.008","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.730845512.793539654","asserted-by":"object"}]},"ISSN":["1743-6109","1743-6095"],"issn-type":[{"value":"1743-6109","type":"electronic"},{"value":"1743-6095","type":"print"}],"subject":[],"published-other":{"date-parts":[[2017,10]]},"published":{"date-parts":[[2017,9,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and Efficacy of Collagenase Clostridium histolyticum in the Treatment of Acute-Phase Peyronie\u2019s Disease","name":"articletitle","label":"Article Title"},{"value":"The Journal of Sexual Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsxm.2017.08.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}